Skip to main content
CDNA logo

CareDx, Inc. (CDNA) Stock: Price, Forecast & Analyst Target

CareDx, Inc. (CDNA) — MoonshotScore 84/100 (Exceptional band), calculated Nov 18, 2026. Price $74.44 (-0.16%), as of the Nov 18, 2026 trading session; market cap $3.91B.

Educational signal · not a buy or sell recommendation · How to read this

$74.44 −$0.12 (-0.16%) Market Cap $3.91B

CareDx, Inc. · CDNA · NASDAQ

CareDx, Inc. is a leading precision medicine company focused on transplant patient care. The company develops and commercializes diagnostic solutions for transplant patients and caregivers globally.

Price as of Nov 18, 2026

Key Statistics

84 of 100

MoonshotScore v2 · CareDx (CDNA)

Exceptional
Business Quality Elite (92)
Financial Safety Sound (69)
Valuation Rich (36)
Growth Durability Growing (65)
Momentum Surging (100)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality and a strong balance sheet, but an expensive valuation; the market is already moving on it. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Sound; Valuation: Rich; Growth Durability: Growing; Momentum: Surging.

  • EPS beat 2 of the last 4 reports
  • Altman Z 13.60 · Piotroski F 6
  • ROE 33.0% · ROA 0.9% · current ratio 2.31

Helping: business quality, balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for CDNA (57 recorded, newest six shown)
RecordedScoreBand
78Strong
78Strong
78Strong
78Strong
84Exceptional
84Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$74.44
Change on the day-0.16%
Market capitalisation$3.91B—
Price / earnings (trailing)29.94
Shares traded on the day537.3K

Price & events

Other perspectives

Council score for CareDx (CDNA): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Moderate
Valuation Weak
Growth Durability Moderate
Momentum Strong

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Unfavorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Moderate
Margin of Safety Overvalued
Profit Margin Strong
Revenue Growth Moderate
Debt/Equity Strong
ROE Strong
Gross Margin Strong

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Three of these lenses read this company less favourably than the MoonshotScore does: Englander-style lens, Moon AI lens and Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as overvalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is CareDx (CDNA), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. CareDx, Inc. (CDNA) is listed on NASDAQ. It employs 761 people. The market values it at $3.91B.

2 · Latest results

What do the latest results show for CareDx (CDNA)?

Short answer · as of

Against analyst estimates the company has EPS beat 2 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$100M$2M$0.03 (diluted)
Q4 FY2025$108M-$4M-$0.08 (diluted)
Q1 FY2026$118M$3M$0.05 (diluted)
Q2 FY2026$132M$111M$2.07 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for CareDx (CDNA)?

Short answer

The MoonshotScore pillars rate business quality, balance-sheet strength, positive momentum as strengths. The distress and quality screens read Altman Z 13.60 · Piotroski F 6. Trailing ratios: ROE 33.0% · ROA 0.9% · current ratio 2.31.

4 · What to check next?

What should you watch next at CareDx (CDNA)?

Short answer · as of

Current published price targets run low $46.00 · high $100.00 · consensus $80.20 · median $92.00 against a quoted price of $74.44 (as of Nov 18, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Score methodology

How is CareDx scored?

Short answer · as of

A same-model peer rank is unavailable in the current peer set. The MoonshotScore combines business quality, financial safety, valuation, growth durability and momentum; open “Why this rating?” for the method and drivers.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$46.00 – $100.00
Consensus target
$80.20
Median target
$92.00

Consensus record · Captured .

Measured against a quoted price of $74.44 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 10, 2026

Transactions
72
Identified insiders
11
Purchases
0
Sales
26
Other transactions
46

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CDNA in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
ARK InvestCathie WoodQ3 20260.60%$104.59MTrimmed −17.6% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about CareDx (CDNA)?

Read these with our analysis →

Investor Questions: CDNA Stock

These answers are editorial: 1 of these 9 answers is drawn from the CDNA research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for CDNA?

CDNA carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. CareDx, Inc. is a leading precision medicine company focused on transplant patient care.

Is CDNA a good stock to buy?

Stock Expert AI does not rate CDNA buy, sell or hold. CareDx, Inc. carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CDNA stock price today?

The last price recorded for CareDx, Inc. (CDNA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the CDNA price target?

The analyst consensus price target for CareDx, Inc. (CDNA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What do analysts say about CDNA stock?

Analyst consensus on CDNA stock is mixed, reflecting the company's growth potential and inherent risks. Key valuation metrics, such as price-to-sales ratio, are closely monitored.

What are the key factors to evaluate for CDNA?

CareDx, Inc. (CDNA) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Focus on non-invasive diagnostic solutions positions CareDx to capitalize on the increasing demand for patient-friendly monitoring technologies in transplant care. Not financial advice.

How frequently does CDNA data refresh on this page?

CDNA's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CDNA's recent stock price performance?

CareDx, Inc. (CDNA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary diagnostic technologies for transplant monitoring. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CDNA overvalued or undervalued right now?

The trailing P/E of CareDx, Inc. (CDNA) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 16 figures on this page — 12 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.